)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
OptiNose
OptiNose (OPTN) investor relations material
OptiNose has been delisted
OptiNose Q4 2024 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q4 2024 earnings summary26 Mar, 2025
Executive summary
XHANCE net revenue reached $22.4 million in Q4 2024 and $78.2 million for the full year, up 13% and 10% year-over-year, respectively.
Prescription demand inflected upward in September 2024, with Q4 NRx up 12% and TRX up 23% sequentially from Q3 2024.
Achieved first-ever positive income from operations in Q4 2024 at $0.4 million.
Financial highlights
Q4 2024 net revenue: $22.4 million (up 13% year-over-year); full year 2024: $78.2 million (up 10%).
Q4 2024 net loss: $0.4 million ($0.04/share); full year 2024 net loss: $21.5 million ($2.12/share), both improved from prior year.
Cash and cash equivalents at year-end: $84.5 million.
SG&A plus R&D expenses for 2024: $87.3 million, up from $85.1 million in 2023.
Weighted average shares outstanding for 2024: 10.2 million.
Segment performance
XHANCE prescriptions showed strong growth: NRx up 12% and TRX up 23% sequentially from Q3 to Q4 2024.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from OptiNose
- Label expansion for XHANCE unlocks a large market, driving growth and strategic opportunities.OPTN
Piper Sandler 36th Annual Healthcare Conference - Q3 revenue up 3% to $20.4M, but 2024 guidance cut and going concern risk remains.OPTNQ3 2024
- FDA approval and expanded launch position XHANCE for major growth in chronic sinusitis treatment.OPTNH.C. Wainwright 26th Annual Global Investment Conference
- New indication and expanded access drove revenue growth and improved 2024 outlook.OPTNQ2 2024
OptiNose
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
OptiNose Inc. is a pharmaceutical company engaged in the development and commercialization of innovative products for patients under the care of ear, nose, throat, and allergy specialists in the United States. The company has developed a proprietary Exhalation Delivery Systems, a novel drug delivery concept that facilitates broad, consistent drug delivery deep within the nasal passages. This technology aims to leverage the mucosal surfaces as a potential target for treating both local and systemic diseases. OptiNose's portfolio includes XHANCE, a therapeutic product utilizing EDS to deliver a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps. Additionally, the company has developed Onzetra Xsail, a powder EDS device, and is exploring further applications of its technology in various clinical trials. OptiNose is headquartered in Yardley, Pennsylvania, and its shares are listed on the NASDAQ.